Fuad El-Hibri Announces Emergent BioSolutionsAward to Supply BioThrax Anthrax Vaccine to U.S. Government
Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc.,(NYSE: EBS) announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion. BioThrax is [...]
October 14, 2011
Tags: Anthrax vaccines, BIOTHRAXВ®, Centers for Disease Control and Prevention, Food and Drug Administration, fuad el-hibri Posted in: BioDefense, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri 
No Comments
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]
July 7, 2011
Tags: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Singapore Ministry of Health Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Health Care, US Food and Drug Administration., fuad el-hibri No Comments
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule
ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]
June 7, 2011
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Strategic National Stockpile Posted in: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, US Food and Drug Administration., fuad el-hibri No Comments
Emergent BioSolutions Reports Financial Results for Full Year 2010
2010 revenues of $286.2 million
2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
2010 cash, investments and accounts receivable balance of $210.4 million
2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million
Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its [...]
April 13, 2011
Tags: Anthrax vaccines, Biothrax, Business, Chief financial officer, Emergent BioSolutions, Financial Results Posted in: Board of Directors, Business, Chief executive officer, Emergent BioSolutions, Financial Results, fuad el-hibri No Comments
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
January 5, 2011
Tags: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, Research and development, United States Department of Health and Human Services, fuad el-hibri No Comments
Fuad El-Hibri and the International Biomedical Research Alliance
The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]
November 13, 2010
Tags: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Infectious disease, Leadership, Medical research Posted in: Biosolutions, Biothrax, El-Hibri, Emergent BioSolutions, Research and development, fuad el-hibri No Comments
Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010
ROCKVILLE, Md., Oct 13, 2010 — Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market close. Company management will host a conference call at 5:00 pm Eastern on November 4, 2010 to discuss the financial results for [...]
October 23, 2010
Tags: Anthrax, Anthrax vaccines, Chief executive officer, Conference call, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, New York Stock Exchange Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, fuad el-hibri No Comments
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
September 20, 2010
Tags: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. Government Posted in: Anthrax vaccines, Biosolutions, Emergent BioSolutions, Research and development, fuad el-hibri No Comments
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
New Contract Valued at up to $28.7 Million for Phase II Clinical Trial
ROCKVILLE, Md., Sep 01, 2010 –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of [...]
September 10, 2010
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, National Institutes of Health, Research and development Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Research and development, fuad el-hibri No Comments
Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]
August 30, 2010
Tags: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Infectious disease, Scholars Program Posted in: Anthrax vaccines, Biosolutions, Business, El-Hibri Peace Education Prize, Emergent BioSolutions, Infectious disease, Scholars Program, fuad el-hibri No Comments